search
Back to results

Azilsartan Circadian and Sleep Pressure

Primary Purpose

Hypertension

Status
Completed
Phase
Not Applicable
Locations
Japan
Study Type
Interventional
Intervention
Azilsartan
Amlodipine
Sponsored by
Sogo Rinsho Médéfi Co., Ltd.
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Hypertension focused on measuring Hypertension

Eligibility Criteria

20 Years - undefined (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • Grade I or II essential hypertension
  • The sitting systolic blood pressure is in term of 140-179 mmHg, or sitting diastolic blood pressure is in term of 90-109 mmHg at the both two time points at the beginning of the observation period and at the beginning of a treatment period (Week0)
  • 20 years old or older at the time of the informed consent
  • Able to give written informed consent before participating in the research
  • Therapeutic category during the observation period: Ambulatory

Exclusion Criteria:

  • Secondary hypertension, grade III hypertension (sitting systolic blood pressure greater than or equal to 180 mmHg or sitting diastolic blood pressure greater than or equal to 110 mmHg), malignant hypertension
  • More than 2 kinds of antihypertensive agents for treatment on the hypertension
  • History of taking following medicines within 2 weeks before start of the observation period.

When subject with taking any of the following medicine at the time of informed consent is included, stop to take the medicine for determined period after the informed consent.

I. Antihypertensive agents II. Antianginal agents III. Antiarrhythmic agents (except single time use of the lidocaine hydrochloride formulation for anesthesia) IV. Digitalis products

  • Less than 130 mmHg of mean 24-hour systolic blood pressure and less than 80 mmHg of mean 24-hour diastolic blood pressure at the start of the observation period.
  • History of following circulatory-related diseases or symptoms within 24 weeks before start of the observation period.

I. Cardiac disease: Myocardial infarction, coronary artery revascularization II. Cerebrovascular-disease: cerebral infarction, cerebral hemorrhage, transient ischemic attack III. Progressive hypertensive retinopathy: hemorrhage, exudation, or papilledema

  • History or complication with the following circulatory-related diseases; Valvular stenosis, atrial fibrillation, pharmacotherapy-required angina, congestion heart failure, or cardiac arrhythmia, or arteriosclerosis obliterans with symptoms of intermittent claudication et al
  • Day / night reversal
  • History of hypersensitivity or allergy to Azilsartan, Amlodipine, or related drugs
  • Participant in any other clinical research
  • Pregnant, possible to being pregnant, or lactating woman
  • Mal-control of blood pressure during informed consent to taking antihypertensive agent
  • Any those the investigator or other researchers consider as unsuitable

Sites / Locations

  • Jyuzen General Hospital
  • Junn Clinic
  • Seikei-kai New Tokyo Hospital
  • Sanshukai Doi Internal Medicine Clinic
  • Junshinkai Nakamura Cardiovascular Clinic
  • Osaki Clinic
  • Osamura Medical Clinic
  • Hoshi General Hospital
  • Zensyukai Hospital
  • Hakushoukai Sano Hospital
  • Jiseikai Higashiasahikawa Hospital
  • Koushinkai Shintomi Naika Clinic
  • Aoki Clinic
  • Houwakai Sapporo Hospital
  • Mitani Clinic
  • Shinkotoni Family Clinic
  • Shoureikan Shinsapporo Seiryou Hospital
  • Tomakomai City Hospital
  • Hukuyo naika clinic
  • Asunaro medical Clinic
  • Keiseikai Gohshi Hospital
  • Keijukai Itabashi Clinic
  • Kamata medical Clinic
  • Koyokai Hanamure Hospital
  • Izumi General Medical Center
  • Iroden Clinic
  • Nagasu Clinic
  • Himawari-kai Kanagawa Himawari Clinic
  • Kawasaki Saiwai Clinic
  • Wakoukai Kawasaki Rinko General Hospital
  • Hakuai Clinic
  • Kaneshiro Diabetes Clinic
  • Yamamoto Clinic
  • Tsuruma Kaneshiro Diabetes Clinic
  • Furuie Clinic
  • Minamisawa Clinic
  • Shintoukai Yokohama Minoru Clinic
  • Shuyu-kai Kikuchi Clinic
  • Tani Clinic
  • Higashikatsuyama Nakazawa Naika Allergy Internal Medicine
  • Shinden Higashi Clinic
  • Meiwakai Izaki Clinic
  • Shoninkai Shonin Hospital
  • Hirano Doujinkai Tsuyama Daiichi Hospital
  • Taira Hospital
  • Tenjin Tanaka Internal Medicine Clinic
  • Enomoto Clinic
  • Kazo Minami Clinic
  • Asukurepiosu Enomoto Clinic
  • Shibuya Clinic
  • Genkikai Wakasa Clinic
  • JA Shizuoka Kohseiren Enshu Hospital
  • Shimoda Medical Center
  • Jichi Medical University Hospital
  • DIC Utsunomiya Central Clinic
  • Nippori Clinic
  • Eireikai Niwa Family Clinic
  • Keiyu Clinic
  • Nihonbashikabutocho Nakajima Clinic
  • Tokyo Center Clinic
  • Taiseikai Seikoudou Clinic
  • Hirookai Kanbara Clinic
  • Ono Medical Clinic
  • Sawai Medical Clinic
  • Shinsei-kai Kameido Ekimae Ckinic
  • Shinseikai Kameido Minami-guchi Clinic
  • Kamada Clinic
  • Mitaka Health Care Clinic
  • Murenosato Clinic
  • Shirayurikai Swing Bldg Nozaki Clinic
  • Kenkoukan Suzuki Clinic
  • Keichikai Shimokitazawa Tomo Clinic
  • Ishinkai Oda Clinic
  • Ryousyukai Kanauchi Medical Clinic
  • Shingakai MaO Clinic
  • Keiseikai Otsuka Kita-guchi Clinic
  • Fujino Clinic
  • Hirokai Higashikatsura Medical Clinic
  • Hakataeki-higashi Clinic
  • Ogata Medical Clinic
  • Soejima Naika Clinic
  • Inoue Neurology Clinic
  • Oda medical Clinic
  • Aiseikai PS Clinic
  • Kosei-kai Nijigaoka Hospital
  • Seizenkai Okayama Saidaiji Hospital
  • Yasuda Clinic
  • AMC Nishiumeda Clinic
  • Kouseikai Chimori Medical Clinic
  • H&Y Akimoto Naika Clinic
  • Shiseidou Tomita Hospital
  • Takahashi Clinic

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

Active Comparator

Arm Label

Azilsartan

Amlodipine

Arm Description

Azilsartan 20mg/day in oral administration, single dose Treatment duration: 8 weeks

Amlodipine 5mg/day in oral administration, single dose Treatment duration: 8 weeks

Outcomes

Primary Outcome Measures

Change in Nocturnal Systolic Blood Pressure Level
Change at the end of a treatment period (Week 8) from the beginning point of an observation period *Nocturnal systolic blood pressure level: the mean value of systolic arterial pressure during night (during sleeping)

Secondary Outcome Measures

Change in the Absolute Value in Difference With Targeted Value* (15 Percent) of Nocturnal Systolic Blood Pressure Fall**
Change from the start of the run-in period (Week -1) at the end of the treatment period (Week 8) *The targeted value has been set as the median of the dipping rate, normal type of nocturnal blood pressure variation, rate of nocturnal blood pressure fall (10-20 percent) ** Rate of nocturnal blood pressure fall: calculated as (awake SBP-sleep SBP)/awake SBP
Change in Nocturnal Diastolic Blood Pressure Level
Change from the start of the run-in period (Week -1) at the end of the treatment period (Week 8)
Change in 24-hour Mean Systolic Blood Pressure Level
Change from the start of the run-in period (Week -1) at the end of the treatment period (Week 8)
Change in 24-hour Mean Diastolic Blood Pressure Level
Change from the start of the run-in period (Week -1) at the end of the treatment period (Week 8)

Full Information

First Posted
December 18, 2012
Last Updated
November 19, 2015
Sponsor
Sogo Rinsho Médéfi Co., Ltd.
Collaborators
Takeda
search

1. Study Identification

Unique Protocol Identification Number
NCT01762501
Brief Title
Azilsartan Circadian and Sleep Pressure
Official Title
Azilsartan Circadian and Sleep Pressure - the 1st Study
Study Type
Interventional

2. Study Status

Record Verification Date
November 2015
Overall Recruitment Status
Completed
Study Start Date
December 2012 (undefined)
Primary Completion Date
December 2013 (Actual)
Study Completion Date
December 2013 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Sogo Rinsho Médéfi Co., Ltd.
Collaborators
Takeda

4. Oversight

Data Monitoring Committee
No

5. Study Description

Brief Summary
To determine the efficacy of Azilsartan 20 mg versus Amlodipine 5 mg oral administration once per day for 8 weeks in patients with grade I or grade II essential hypertension.
Detailed Description
Treatment <Run-in period> Use of any antihypertensives, including azilsartan and amlodipine, is prohibited during the run-in period. <Treatment period> Subjects who are considered eligible for participation in the study based on the results of eligibility assessment during the run-in period will be randomized to the azilsartan 20 mg or amlodipine 5 mg group at a ratio of 1:1 according to the following stratification factors; the type of awake-sleep blood pressure variation determined based on the data from ABPM at the start of run-in, complication status (chronic kidney diseases [CKD], type 2 diabetes), age, and sex. Subjects will start treatment with either antihypertensive after examination for the start of treatment (Week 0) and visit the study site every 2 weeks, 5 visits in total, until the end of treatment (Week 8). Subjects will orally take azilsartan 20 mg or amlodipine 5 mg, according to their group allocation, once daily before or after breakfast in the morning.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Hypertension
Keywords
Hypertension

7. Study Design

Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Masking
None (Open Label)
Allocation
Randomized
Enrollment
957 (Actual)

8. Arms, Groups, and Interventions

Arm Title
Azilsartan
Arm Type
Experimental
Arm Description
Azilsartan 20mg/day in oral administration, single dose Treatment duration: 8 weeks
Arm Title
Amlodipine
Arm Type
Active Comparator
Arm Description
Amlodipine 5mg/day in oral administration, single dose Treatment duration: 8 weeks
Intervention Type
Drug
Intervention Name(s)
Azilsartan
Other Intervention Name(s)
AZILVA Tablets
Intervention Description
Azilsartan 20mg/day
Intervention Type
Drug
Intervention Name(s)
Amlodipine
Other Intervention Name(s)
Amlodin Tablets etc.
Intervention Description
Amlodipine 5mg/day
Primary Outcome Measure Information:
Title
Change in Nocturnal Systolic Blood Pressure Level
Description
Change at the end of a treatment period (Week 8) from the beginning point of an observation period *Nocturnal systolic blood pressure level: the mean value of systolic arterial pressure during night (during sleeping)
Time Frame
Baseline and 8 weeks
Secondary Outcome Measure Information:
Title
Change in the Absolute Value in Difference With Targeted Value* (15 Percent) of Nocturnal Systolic Blood Pressure Fall**
Description
Change from the start of the run-in period (Week -1) at the end of the treatment period (Week 8) *The targeted value has been set as the median of the dipping rate, normal type of nocturnal blood pressure variation, rate of nocturnal blood pressure fall (10-20 percent) ** Rate of nocturnal blood pressure fall: calculated as (awake SBP-sleep SBP)/awake SBP
Time Frame
Baseline and 8 weeks
Title
Change in Nocturnal Diastolic Blood Pressure Level
Description
Change from the start of the run-in period (Week -1) at the end of the treatment period (Week 8)
Time Frame
Baseline and 8 weeks
Title
Change in 24-hour Mean Systolic Blood Pressure Level
Description
Change from the start of the run-in period (Week -1) at the end of the treatment period (Week 8)
Time Frame
Baseline and 8 weeks
Title
Change in 24-hour Mean Diastolic Blood Pressure Level
Description
Change from the start of the run-in period (Week -1) at the end of the treatment period (Week 8)
Time Frame
Baseline and 8 weeks

10. Eligibility

Sex
All
Minimum Age & Unit of Time
20 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Grade I or II essential hypertension The sitting systolic blood pressure is in term of 140-179 mmHg, or sitting diastolic blood pressure is in term of 90-109 mmHg at the both two time points at the beginning of the observation period and at the beginning of a treatment period (Week0) 20 years old or older at the time of the informed consent Able to give written informed consent before participating in the research Therapeutic category during the observation period: Ambulatory Exclusion Criteria: Secondary hypertension, grade III hypertension (sitting systolic blood pressure greater than or equal to 180 mmHg or sitting diastolic blood pressure greater than or equal to 110 mmHg), malignant hypertension More than 2 kinds of antihypertensive agents for treatment on the hypertension History of taking following medicines within 2 weeks before start of the observation period. When subject with taking any of the following medicine at the time of informed consent is included, stop to take the medicine for determined period after the informed consent. I. Antihypertensive agents II. Antianginal agents III. Antiarrhythmic agents (except single time use of the lidocaine hydrochloride formulation for anesthesia) IV. Digitalis products Less than 130 mmHg of mean 24-hour systolic blood pressure and less than 80 mmHg of mean 24-hour diastolic blood pressure at the start of the observation period. History of following circulatory-related diseases or symptoms within 24 weeks before start of the observation period. I. Cardiac disease: Myocardial infarction, coronary artery revascularization II. Cerebrovascular-disease: cerebral infarction, cerebral hemorrhage, transient ischemic attack III. Progressive hypertensive retinopathy: hemorrhage, exudation, or papilledema History or complication with the following circulatory-related diseases; Valvular stenosis, atrial fibrillation, pharmacotherapy-required angina, congestion heart failure, or cardiac arrhythmia, or arteriosclerosis obliterans with symptoms of intermittent claudication et al Day / night reversal History of hypersensitivity or allergy to Azilsartan, Amlodipine, or related drugs Participant in any other clinical research Pregnant, possible to being pregnant, or lactating woman Mal-control of blood pressure during informed consent to taking antihypertensive agent Any those the investigator or other researchers consider as unsuitable
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Kazuo Kario
Organizational Affiliation
Chief Professor of Division of Cardiovascular Medicine, Jichi Medical University
Official's Role
Principal Investigator
Facility Information:
Facility Name
Jyuzen General Hospital
City
Niihama
State/Province
Aichi
Country
Japan
Facility Name
Junn Clinic
City
Tsushima
State/Province
Aichi
Country
Japan
Facility Name
Seikei-kai New Tokyo Hospital
City
Matsudo
State/Province
Chiba
Country
Japan
Facility Name
Sanshukai Doi Internal Medicine Clinic
City
Chikushino
State/Province
Fukuoka
Country
Japan
Facility Name
Junshinkai Nakamura Cardiovascular Clinic
City
Itoshima
State/Province
Fukuoka
Country
Japan
Facility Name
Osaki Clinic
City
Kitakyusyu
State/Province
Fukuoka
Country
Japan
Facility Name
Osamura Medical Clinic
City
Kitakyusyu
State/Province
Fukuoka
Country
Japan
Facility Name
Hoshi General Hospital
City
Koriyama
State/Province
Fukushima
Country
Japan
Facility Name
Zensyukai Hospital
City
Maebashi
State/Province
Gunma
Country
Japan
Facility Name
Hakushoukai Sano Hospital
City
Asahikawa
State/Province
Hokkaido
Country
Japan
Facility Name
Jiseikai Higashiasahikawa Hospital
City
Asahikawa
State/Province
Hokkaido
Country
Japan
Facility Name
Koushinkai Shintomi Naika Clinic
City
Asahikawa
State/Province
Hokkaido
Country
Japan
Facility Name
Aoki Clinic
City
Sapporo
State/Province
Hokkaido
Country
Japan
Facility Name
Houwakai Sapporo Hospital
City
Sapporo
State/Province
Hokkaido
Country
Japan
Facility Name
Mitani Clinic
City
Sapporo
State/Province
Hokkaido
Country
Japan
Facility Name
Shinkotoni Family Clinic
City
Sapporo
State/Province
Hokkaido
Country
Japan
Facility Name
Shoureikan Shinsapporo Seiryou Hospital
City
Sapporo
State/Province
Hokkaido
Country
Japan
Facility Name
Tomakomai City Hospital
City
Tomakomai
State/Province
Hokkaido
Country
Japan
Facility Name
Hukuyo naika clinic
City
Itoshima
State/Province
Hukuoka
Country
Japan
Facility Name
Asunaro medical Clinic
City
Kitakyushu
State/Province
Hukuoka
Country
Japan
Facility Name
Keiseikai Gohshi Hospital
City
Amagasaki
State/Province
Hyogo
Country
Japan
Facility Name
Keijukai Itabashi Clinic
City
Koga
State/Province
Ibaraki
Country
Japan
Facility Name
Kamata medical Clinic
City
Morioka
State/Province
Iwate
Country
Japan
Facility Name
Koyokai Hanamure Hospital
City
Ichikikushikino
State/Province
Kagoshima
Country
Japan
Facility Name
Izumi General Medical Center
City
Izumi
State/Province
Kagoshima
Country
Japan
Facility Name
Iroden Clinic
City
Kamakura
State/Province
Kanagawa
Country
Japan
Facility Name
Nagasu Clinic
City
Kamakura
State/Province
Kanagawa
Country
Japan
Facility Name
Himawari-kai Kanagawa Himawari Clinic
City
Kawasaki
State/Province
Kanagawa
Country
Japan
Facility Name
Kawasaki Saiwai Clinic
City
Kawasaki
State/Province
Kanagawa
Country
Japan
Facility Name
Wakoukai Kawasaki Rinko General Hospital
City
Kawasaki
State/Province
Kanagawa
Country
Japan
Facility Name
Hakuai Clinic
City
Sagamihara
State/Province
Kanagawa
Country
Japan
Facility Name
Kaneshiro Diabetes Clinic
City
Sagamihara
State/Province
Kanagawa
Country
Japan
Facility Name
Yamamoto Clinic
City
Sagamihara
State/Province
Kanagawa
Country
Japan
Facility Name
Tsuruma Kaneshiro Diabetes Clinic
City
Yamato
State/Province
Kanagawa
Country
Japan
Facility Name
Furuie Clinic
City
Yokohama
State/Province
Kanagawa
Country
Japan
Facility Name
Minamisawa Clinic
City
Yokohama
State/Province
Kanagawa
Country
Japan
Facility Name
Shintoukai Yokohama Minoru Clinic
City
Yokohama
State/Province
Kanagawa
Country
Japan
Facility Name
Shuyu-kai Kikuchi Clinic
City
Yokohama
State/Province
Kanagawa
Country
Japan
Facility Name
Tani Clinic
City
Yokohama
State/Province
Kanagawa
Country
Japan
Facility Name
Higashikatsuyama Nakazawa Naika Allergy Internal Medicine
City
Sendai
State/Province
Miyagi
Country
Japan
Facility Name
Shinden Higashi Clinic
City
Sendai
State/Province
Miyagi
Country
Japan
Facility Name
Meiwakai Izaki Clinic
City
Omura
State/Province
Nagasaki
Country
Japan
Facility Name
Shoninkai Shonin Hospital
City
Beppu
State/Province
Oita
Country
Japan
Facility Name
Hirano Doujinkai Tsuyama Daiichi Hospital
City
Tsuyama
State/Province
Okayama
Country
Japan
Facility Name
Taira Hospital
City
Wake-gun
State/Province
Okayama
Country
Japan
Facility Name
Tenjin Tanaka Internal Medicine Clinic
City
Takatsuki
State/Province
Osaka
Country
Japan
Facility Name
Enomoto Clinic
City
Ageo
State/Province
Saitama
Country
Japan
Facility Name
Kazo Minami Clinic
City
Kazo
State/Province
Saitama
Country
Japan
Facility Name
Asukurepiosu Enomoto Clinic
City
Kumagaya
State/Province
Saitama
Country
Japan
Facility Name
Shibuya Clinic
City
Kumagaya
State/Province
Saitama
Country
Japan
Facility Name
Genkikai Wakasa Clinic
City
Tokorozawa
State/Province
Saitama
Country
Japan
Facility Name
JA Shizuoka Kohseiren Enshu Hospital
City
Hamamatsu
State/Province
Shizuoka
Country
Japan
Facility Name
Shimoda Medical Center
City
Shimoda
State/Province
Shizuoka
Country
Japan
Facility Name
Jichi Medical University Hospital
City
Shimotsuke
State/Province
Tochigi
Country
Japan
Facility Name
DIC Utsunomiya Central Clinic
City
Utsunomiya
State/Province
Tochigi
Country
Japan
Facility Name
Nippori Clinic
City
Arakawa-ku
State/Province
Tokyo
Country
Japan
Facility Name
Eireikai Niwa Family Clinic
City
Chofu
State/Province
Tokyo
Country
Japan
Facility Name
Keiyu Clinic
City
Chuo-ku
State/Province
Tokyo
Country
Japan
Facility Name
Nihonbashikabutocho Nakajima Clinic
City
Chuo-ku
State/Province
Tokyo
Country
Japan
Facility Name
Tokyo Center Clinic
City
Chuo-ku
State/Province
Tokyo
Country
Japan
Facility Name
Taiseikai Seikoudou Clinic
City
Edogawa-ku
State/Province
Tokyo
Country
Japan
Facility Name
Hirookai Kanbara Clinic
City
Koto-ku
State/Province
Tokyo
Country
Japan
Facility Name
Ono Medical Clinic
City
Koto-ku
State/Province
Tokyo
Country
Japan
Facility Name
Sawai Medical Clinic
City
Koto-ku
State/Province
Tokyo
Country
Japan
Facility Name
Shinsei-kai Kameido Ekimae Ckinic
City
Koto-ku
State/Province
Tokyo
Country
Japan
Facility Name
Shinseikai Kameido Minami-guchi Clinic
City
Koto-ku
State/Province
Tokyo
Country
Japan
Facility Name
Kamada Clinic
City
Mitaka
State/Province
Tokyo
Country
Japan
Facility Name
Mitaka Health Care Clinic
City
Mitaka
State/Province
Tokyo
Country
Japan
Facility Name
Murenosato Clinic
City
Mitaka
State/Province
Tokyo
Country
Japan
Facility Name
Shirayurikai Swing Bldg Nozaki Clinic
City
Musashino
State/Province
Tokyo
Country
Japan
Facility Name
Kenkoukan Suzuki Clinic
City
Ota-ku
State/Province
Tokyo
Country
Japan
Facility Name
Keichikai Shimokitazawa Tomo Clinic
City
Setagaya-ku
State/Province
Tokyo
Country
Japan
Facility Name
Ishinkai Oda Clinic
City
Shinjuku-ku
State/Province
Tokyo
Country
Japan
Facility Name
Ryousyukai Kanauchi Medical Clinic
City
Shinjuku-ku
State/Province
Tokyo
Country
Japan
Facility Name
Shingakai MaO Clinic
City
Suginami-ku
State/Province
Tokyo
Country
Japan
Facility Name
Keiseikai Otsuka Kita-guchi Clinic
City
Toshima-ku
State/Province
Tokyo
Country
Japan
Facility Name
Fujino Clinic
City
Ube
State/Province
Yamaguchi
Country
Japan
Facility Name
Hirokai Higashikatsura Medical Clinic
City
Tsuru
State/Province
Yamanashi
Country
Japan
Facility Name
Hakataeki-higashi Clinic
City
Fukuoka
Country
Japan
Facility Name
Ogata Medical Clinic
City
Fukuoka
Country
Japan
Facility Name
Soejima Naika Clinic
City
Fukuoka
Country
Japan
Facility Name
Inoue Neurology Clinic
City
Hiroshima
Country
Japan
Facility Name
Oda medical Clinic
City
Hiroshima
Country
Japan
Facility Name
Aiseikai PS Clinic
City
Hukuoka
Country
Japan
Facility Name
Kosei-kai Nijigaoka Hospital
City
Nagasaki
Country
Japan
Facility Name
Seizenkai Okayama Saidaiji Hospital
City
Okayama
Country
Japan
Facility Name
Yasuda Clinic
City
Okayama
Country
Japan
Facility Name
AMC Nishiumeda Clinic
City
Osaka
Country
Japan
Facility Name
Kouseikai Chimori Medical Clinic
City
Osaka
Country
Japan
Facility Name
H&Y Akimoto Naika Clinic
City
Saitama
Country
Japan
Facility Name
Shiseidou Tomita Hospital
City
Saitama
Country
Japan
Facility Name
Takahashi Clinic
City
Saitama
Country
Japan

12. IPD Sharing Statement

Citations:
PubMed Identifier
25646296
Citation
Kario K, Hoshide S. Age-related difference in the sleep pressure-lowering effect between an angiotensin II receptor blocker and a calcium channel blocker in Asian hypertensives: the ACS1 Study. Hypertension. 2015 Apr;65(4):729-35. doi: 10.1161/HYPERTENSIONAHA.114.04935. Epub 2015 Feb 2.
Results Reference
derived

Learn more about this trial

Azilsartan Circadian and Sleep Pressure

We'll reach out to this number within 24 hrs